11549293

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new

```
                  custom IPC display formats
 NEWS 32  JAN 28  MARPAT searching enhanced
 NEWS 33  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:59:57 ON 14 FEB 2008

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:00:26 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   13 FEB 2008  HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES:  13 FEB 2008  HIGHEST RN 1003293-96-6
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560771.str





chain nodes :
12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 16 17 18
chain bonds :
4-13 9-12 12-13 12-15 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 6-18 7-8 7-16 8-9 9-10 10-11 16-17 17-18

exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-13 6-7 6-11 6-18 7-8 7-16 8-9 9-10 9-12 10-11
12-13 12-15 13-14 16-17 17-18
isolated ring systems :
containing 1 : 6 :

G1:O,S,N,NH

G2:CH2,CH,CF2,CF3

G3:CH2,CF2,CF3,SO2,SO3H,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,NH

G2 CH2,CH,CF2,CF3

G3 CH2,CF2,CF3,SO2,SO3H,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:00:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        9 TO ITERATE

100.0% PROCESSED        9 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            9 TO      360
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 11:00:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      161 TO ITERATE

100.0% PROCESSED      161 ITERATIONS                                7 ANSWERS
SEARCH TIME: 00.00.01

L3            7 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                  178.36     178.57

FILE 'HCAPLUS' ENTERED AT 11:01:00 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Feb 2008  VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008  (20080213/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s l3
L4            5 L3

=> s l4 and py<=2003
```

```
      23976331 PY<=2003
L5           5 L4 AND PY<=2003

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:2864  HCAPLUS
DOCUMENT NUMBER:          140:59935
TITLE:                    Preparation of crystalline (R)-2-(4-
                          amidinophenylaminomethyl)-1-methyl-5-(1-
                          (carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-
                          benzimidazole esters and/or salts for use as
                          antithrombotic agents
INVENTOR(S):              Linz, Guenter; Sieger, Peter; Schreiner, Gunnar; Rall,
                          Werner; Schmid, Rolf
PATENT ASSIGNEE(S):       Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
SOURCE:                   PCT Int. Appl., 33 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    -------------------    --------
     WO 2004000818         A1    20031231    WO 2003-EP6317         20030616
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     DE 10227666           A1    20040108    DE 2002-10227666       20020620
     CA 2485545            A1    20031231    CA 2003-2485545        20030616
     AU 2003237945         A1    20040106    AU 2003-237945         20030616
     EP 1529035            A1    20050511    EP 2003-735629         20030616
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006508037         T     20060309    JP 2004-514726         20030616
     US 2004010026         A1    20040115    US 2003-463033         20030617
     US 7169934            B2    20070130
     US 2007099974         A1    20070503    US 2006-610187         20061213
     US 7294721            B2    20071113
PRIORITY APPLN. INFO.:                       DE 2002-10227666    A  20020620
                                             US 2002-395188P     P  20020711
                                             WO 2003-EP6317      W  20030616
                                             US 2003-463033      A3 20030617
OTHER SOURCE(S):          MARPAT 140:59935
AB   The invention relates to the crystalline forms of compds. (R)-2-(4-
     amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1-
     (pyrrolidinocarbonyl)-ethyl)-benzimidazole and monohydrochloride thereof,
     to methods for the production thereof, and to their use as medicaments having
     an antithrombotic action (no data).  Thus, (R)-2-(4-
```

cyanophenylaminomethyl)-1-methyl-5-[1-amino-1-(pyrrolidineocarbonyl)-ethyl]benzimidazole was simultaneously N-alkylated and CN-reduced/aminated using BrCH2C(O)OCH2CH2CH3 in N-methylpyyolidinone, Pr acetate, and diisopropyethylamine; the resulting ester product was first isolated as the hydrochloride, and then as the 4-toluenesulfonic acid salt, which was deesterified to give the free base. The Et ester was similarly prepared Crystal structure data were given for the free base and the monohydrochloride forms.

IT 253797-00-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and x-ray crystallog. structure of 2-(4-amidinophenylaminomethyl))-1-methyl-5-(1-(carboxymethylamino)benzimidazole esters and/or salts for use as antithrombotic agents)

RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2693 HCAPLUS
DOCUMENT NUMBER: 140:53413
TITLE: Benzimidazole derivatives for the treatment of systemic inflammatory response syndrome
INVENTOR(S): Ries, Uwe; Wienen, Wolfgang; Schuly, Uwe
PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000310	A1	20031231	WO 2003-EP6318	20030616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10227668	A1	20040108	DE 2002-10227668	20020620
CA 2489545	A1	20031231	CA 2003-2489545	20030616
AU 2003278945	A1	20040106	AU 2003-278945	20030616
EP 1517687	A1	20050330	EP 2003-740255	20030616
EP 1517687	B1	20070620		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006514603	T	20060511	JP 2004-514727	20030616
AT 365038	T	20070715	AT 2003-740255	20030616
ES 2289305	T3	20080201	ES 2003-740255	20030616
US 2004023975	A1	20040205	US 2003-600055	20030620

PRIORITY APPLN. INFO.: DE 2002-10227668 A 20020620
US 2002-400166P P 20020801
WO 2003-EP6318 W 20030616

OTHER SOURCE(S): MARPAT 140:53413

AB The invention discloses the use of benzimidazole derivs. for producing a medicament used for treating the systemic inflammatory response syndrome and particularly sepsis. Preparation of (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)ethyl]benzimidazol e hydrochloride is described.

IT 253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzimidazole derivs. for treatment of systemic inflammatory response syndrome)

RN 253797-00-1 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:467997 HCAPLUS

DOCUMENT NUMBER: 135:61338

TITLE: Preparation of 2-(4-amidinophenylaminomethyl)benzimida zoles as antithrombotics

INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962329	A1	20010628	DE 1999-19962329	19991223
US 2001006977	A1	20010705	US 2000-735159	20001212
US 6451832	B2	20020917		
CA 2393916	A1	20010705	CA 2000-2393916	20001216
WO 2001047896	A1	20010705	WO 2000-EP12841	20001216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244636	A1	20021002	EP 2000-983342	20001216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519129	T	20030617	JP 2001-549368	20001216
MX 2002PA06299	A	20021209	MX 2002-PA6299	20020621
US 2003004356	A1	20030102	US 2002-188952	20020703
US 6593355	B2	20030715		

PRIORITY APPLN. INFO.:		
DE 1999-19962329	A	19991223
US 2000-175163P	P	20000107
US 2000-735159	A1	20001212
WO 2000-EP12841	W	20001216

OTHER SOURCE(S): MARPAT 135:61338
GI



I

AB Title compds. [I; R1 = alkyl, fluoroalkyl, pyrrolidinocarbonylalkyl, 2,5-dihydropyrrolocarbonylalkyl, aminoalkyl, etc., R2 = alkyl; R3 = carbamidoyl, cyano, (substituted) oxadiazolyl, etc.] and stereoisomerics thereof were prepared .Thus, (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(ethoxycarbonylmethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl] benzimidazole dihydrochloride in H2O was stirred with NaOH for 45 min. at room temperature followed by addition of HCl up to pH = 3.5 to give 100% (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl]benzimidazole dihydrochloride. Several I extended (doubled) the activated partial thromboplastin time (aPTT) with ED200 = 0.12-0.22 μM.

IT 253797-00-1P 345957-57-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of amidinophenylaminomethylbenzimidazoles as antithrombotics)
RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345957-57-5 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:34881 HCAPLUS
DOCUMENT NUMBER: 132:78556
TITLE: Preparation of amidinophenylaminomethylenzimidazoles as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000001704	A2	20000113	WO 1999-EP4531	19990701
WO 2000001704	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19829964	A1	20000105	DE 1998-19829964	19980704
DE 19857202	A1	20000615	DE 1998-19857202	19981211
DE 19912690	A1	20000921	DE 1999-19912690	19990320
CA 2337804	A1	20000113	CA 1999-2337804	19990701
AU 9949033	A	20000124	AU 1999-49033	19990701
AU 763094	B2	20030710		
BR 9911826	A	20010327	BR 1999-11826	19990701
EP 1095025	A2	20010502	EP 1999-932765	19990701
EP 1095025	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100009	A	20020617	EE 2001-9	19990701
EE 4236	B1	20040216		
JP 2002519429	T	20020702	JP 2000-558106	19990701
AT 229511	T	20021215	AT 1999-932765	19990701
NZ 509625	A	20030829	NZ 1999-509625	19990701
SK 283744	B6	20031202	SK 2001-8	19990701
MX 2000PA12819	A	20040603	MX 2000-PA12819	20001219
IN 2000MN00760	A	20070615	IN 2000-MN760	20001221
NO 2001000028	A	20010103	NO 2001-28	20010103
BG 105111	A	20011231	BG 2001-105111	20010103
HR 2001000007	A1	20011231	HR 2001-7	20010103
HR 2001000007	B1	20030430		
HK 1036976	A1	20041119	HK 2001-107199	20011015

PRIORITY APPLN. INFO.:

DE 1998-19829964	A	19980704
DE 1998-19857202	A	19981211
DE 1999-19912690	A	19990320
WO 1999-EP4531	W	19990701

OTHER SOURCE(S): MARPAT 132:78556

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, pyrazinylene, pyrimidinylene, pyridazinylene; A = alkylene; B = O, S, CH2, CO, imino, SO, SO2; R2 = R1COX, etc.; R1 = alkoxy, amino, alkylamino, dialkylamino, etc.; X = cycloalkylene; R3 = H, alkyl; R4 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride (multistep preparation

given) showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P 253796-87-1P
253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253431-62-8 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS

CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253796-87-1 HCAPLUS
CN Pyrrolidine, 1-[2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:15648 HCAPLUS
DOCUMENT NUMBER: 132:64257
TITLE: Preparation of amidinophenylaminomethylbenzimidazoles and related compounds as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 38 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19829964	A1	20000105	DE 1998-19829964	19980704
US 6248770	B1	20010619	US 1999-338970	19990624
TW 248435	B	20060201	TW 1999-88110926	19990629
CA 2337804	A1	20000113	CA 1999-2337804	19990701
WO 2000001704	A2	20000113	WO 1999-EP4531	19990701
WO 2000001704	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9949033	A	20000124	AU 1999-49033	19990701
AU 763094	B2	20030710		
BR 9911826	A	20010327	BR 1999-11826	19990701
EP 1095025	A2	20010502	EP 1999-932765	19990701
EP 1095025	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100148	T2	20010921	TR 2001-148	19990701
EE 200100009	A	20020617	EE 2001-9	19990701
EE 4236	B1	20040216		
HU 2002000710	A2	20020629	HU 2002-710	19990701
HU 2002000710	A3	20030528		
JP 2002519429	T	20020702	JP 2000-558106	19990701
AT 229511	T	20021215	AT 1999-932765	19990701
PT 1095025	T	20030430	PT 1999-932765	19990701
ES 2188192	T3	20030616	ES 1999-932765	19990701
NZ 509625	A	20030829	NZ 1999-509625	19990701
SK 283744	B6	20031202	SK 2001-8	19990701
ZA 2000007624	A	20010716	ZA 2000-7624	20001219
MX 2000PA12819	A	20040603	MX 2000-PA12819	20001219
IN 2000MN00760	A	20070615	IN 2000-MN760	20001221
NO 2001000028	A	20010103	NO 2001-28	20010103
BG 105111	A	20011231	BG 2001-105111	20010103
HR 2001000007	A1	20011231	HR 2001-7	20010103
HR 2001000007	B1	20030430		
HK 1036976	A1	20041119	HK 2001-107199	20011015

PRIORITY APPLN. INFO.:	DE 1998-19829964	A	19980704
	US 1998-92215P	P	19980709
	DE 1998-19857202	A	19981211
	DE 1999-19912690	A	19990320
	WO 1999-EP4531	W	19990701

OTHER SOURCE(S): MARPAT 132:64257

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, etc.; A = alkylene; B = O, S, CH2, CO, imino, sulfinyl, sulfonyl, etc.; R5 = R1COX; X = cycloalkylene; R1 = (substituted) (di)alkylamino, cycloalkyleneimino, morpholino, piperazino; R5 = H, alkyl; R7 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride [prepared starting from 1-(4-chlorophenyl)-1-cyclopropanecarboxylic acid] showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253431-62-8 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS
CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	51.46	230.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

FILE 'REGISTRY' ENTERED AT 11:06:09 ON 14 FEB 2008

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6
DICTIONARY FILE UPDATES: 13 FEB 2008 HIGHEST RN 1003293-96-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10560771a.str





chain nodes :
12 13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 16 17 18
chain bonds :
4-13 9-12 12-13 12-15 13-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 6-18 7-8 7-16 8-9 9-10 10-11 16-17 17-18

exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 4-13 6-7 6-11 6-18 7-8 7-16 8-9 9-10 9-12 10-11
12-13 12-15 13-14 16-17 17-18
isolated ring systems :
containing 1 : 6 :

G1:O,S,N,NH

G2:CH2,CH,CF2,CF3

G3:CH2,CF2,CF3,SO2,SO3H,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 O,S,N,NH

G2 CH2,CH,CF2,CF3

G3 CH2,CF2,CF3,SO2,SO3H,S

Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 11:06:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

```
PROJECTED ITERATIONS:            9 TO      360
PROJECTED ANSWERS:               0 TO        0

L7            0 SEA SSS SAM L6

=> s l6 sss full
FULL SEARCH INITIATED 11:06:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      161 TO ITERATE

100.0% PROCESSED      161 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L8            0 SEA SSS FUL L6

=>
Uploading C:\Program Files\Stnexp\Queries\10560771b.str
```





```
chain nodes :
12  13  14  15
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  16  17  18
chain bonds :
4-13  9-12  12-13  12-15  13-14
ring bonds :
1-2  1-5  2-3  3-4  4-5  6-7  6-11  6-18  7-8  7-16  8-9  9-10  10-11  16-17  17-18

exact/norm bonds :
1-2  1-5  2-3  3-4  4-5  4-13  6-7  6-11  6-18  7-8  7-16  8-9  9-10  9-12  10-11
12-13  12-15  13-14  16-17  17-18
isolated ring systems :
containing 1 : 6 :
```

11549293

G1:O,S,N,NH

G2:CH2,CH,CF2,CF3

G3:CH2,CF2,CF3,SO2,SO3H,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR



G1 O,S,N,NH

G2 CH2,CH,CF2,CF3

G3 CH2,CF2,CF3,SO2,SO3H,S

Structure attributes must be viewed using STN Express query preparation.

=> s l9
SAMPLE SEARCH INITIATED 11:11:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9 TO ITERATE

100.0% PROCESSED 9 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 9 TO 360
PROJECTED ANSWERS: 1 TO 80

L10 1 SEA SSS SAM L9

=> s l9 sss full
FULL SEARCH INITIATED 11:11:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 161 TO ITERATE

100.0% PROCESSED 161 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

L11 25 SEA SSS FUL L9

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 359.94 589.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -4.00

FILE 'HCAPLUS' ENTERED AT 11:11:41 ON 14 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 14 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 13 Feb 2008 (20080213/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l11
L12 6 L11

=> s l12 and py<=2003
23976331 PY<=2003
L13 5 L12 AND PY<=2003

```
=> s l12 and dipeptidyl peptidase
          4914 DIPEPTIDYL
         14336 PEPTIDASE
          4930 PEPTIDASES
         16580 PEPTIDASE
                (PEPTIDASE OR PEPTIDASES)
          3041 DIPEPTIDYL PEPTIDASE
                (DIPEPTIDYL(W)PEPTIDASE)
L14          1 L12 AND DIPEPTIDYL PEPTIDASE

=> d l12 ibib abs hitstr tot

L12  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:1156435  HCAPLUS
DOCUMENT NUMBER:          142:86665
TITLE:                    Cyclohexylglycine derivatives as dipeptidyl peptidase
                          IV inhibitors for the treatment or prevention of
                          diabetes and other dipeptidyl peptidase IV-associated
                          diseases
INVENTOR(S):              Edmondson, Scott D.; Mastracchio, Anthony; Parmee,
                          Emma R.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 54 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2004112701         A2    20041229    WO 2004-US18718          20040610
     WO 2004112701         A3    20050210
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004249163         A1    20041229    AU 2004-249163           20040610
     CA 2527806            A1    20041229    CA 2004-2527806          20040610
     EP 1638950            A2    20060329    EP 2004-755091           20040610
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1809544            A     20060726    CN 2004-80016974         20040610
     JP 2006528131         T     20061214    JP 2006-517234           20040610
     IN 2005DN05637        A     20080201    IN 2005-DN5637           20051205
     US 2007021477         A1    20070125    US 2005-560771           20051213
PRIORITY APPLN. INFO.:                       US 2003-479246P     P    20030617
                                             WO 2004-US18718     W    20040610
OTHER SOURCE(S):          MARPAT 142:86665
```

AB The invention discloses cyclohexylglycine derivs. which are inhibitors of dipeptidyl peptidase IV which are useful in the treatment or prevention of diseases in which dipeptidyl peptidase IV is involved, such as diabetes and particularly type 2 diabetes. The invention also discloses pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved. Preparation of compds. and intermediates is described.

IT 815580-74-6 815580-74-6D, derivs. 815580-75-7 815580-75-7D, derivs. 815580-76-8 815580-76-8D, derivs. 815580-77-9 815580-77-9D, derivs. 815580-79-1 815580-79-1D, derivs. 815580-80-4 815580-80-4D, derivs. 815580-87-1 815580-87-1D, derivs. 815580-88-2 815580-88-2D, derivs. 815580-89-3 815580-89-3D, derivs. 815580-90-6 815580-90-6D, derivs. 815580-91-7 815580-91-7D, derivs. 815580-92-8 815580-92-8D, derivs. 815580-93-9 815580-93-9D, derivs. 815580-94-0 815580-94-0D, derivs. 815580-95-1 815580-95-1D, derivs. 815580-96-2 815580-96-2D, derivs. 815580-97-3 815580-97-3D, derivs. 815580-98-4 815580-98-4D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclohexylglycine derivs. as dipeptidyl peptidase IV inhibitors for treatment or prevention of diabetes and other dipeptidyl peptidase IV-associated diseases)

RN 815580-74-6 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-74-6 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-75-7 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-75-7 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-76-8 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-76-8 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-77-9 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-77-9 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-79-1 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-79-1 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-80-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-

difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-80-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-87-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-87-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-88-2 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-88-2 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-89-3 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-89-3 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-90-6 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-90-6 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-91-7 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-91-7 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-92-8 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-
difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-92-8 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-93-9 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-93-9 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-94-0 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-94-0 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-95-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-95-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-96-2 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-96-2 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-97-3 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-97-3 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-98-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-

3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-98-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2864 HCAPLUS
DOCUMENT NUMBER: 140:59935
TITLE: Preparation of crystalline (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazole esters and/or salts for use as antithrombotic agents
INVENTOR(S): Linz, Guenter; Sieger, Peter; Schreiner, Gunnar; Rall, Werner; Schmid, Rolf
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000818	A1	20031231	WO 2003-EP6317	20030616

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10227666	A1	20040108	DE 2002-10227666	20020620
CA 2485545	A1	20031231	CA 2003-2485545	20030616
AU 2003237945	A1	20040106	AU 2003-237945	20030616
EP 1529035	A1	20050511	EP 2003-735629	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508037	T	20060309	JP 2004-514726	20030616
US 2004010026	A1	20040115	US 2003-463033	20030617
US 7169934	B2	20070130		
US 2007099974	A1	20070503	US 2006-610187	20061213
US 7294721	B2	20071113		

PRIORITY APPLN. INFO.:	DE 2002-10227666	A 20020620
	US 2002-395188P	P 20020711
	WO 2003-EP6317	W 20030616
	US 2003-463033	A3 20030617

OTHER SOURCE(S): MARPAT 140:59935

AB The invention relates to the crystalline forms of compds. (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl)-benzimidazole and monohydrochloride thereof, to methods for the production thereof, and to their use as medicaments having an antithrombotic action (no data). Thus, (R)-2-(4-cyanophenylaminomethyl)-1-methyl-5-[1-amino-1-(pyrrolidineocarbonyl)-ethyl]benzimidazole was simultaneously N-alkylated and CN-reduced/aminated using BrCH2C(O)OCH2CH2CH3 in N-methylpyyolidinone, Pr acetate, and diisopropyethylamine; the resulting ester product was first isolated as the hydrochloride, and then as the 4-toluenesulfonic acid salt, which was deesterified to give the free base. The Et ester was similarly prepared Crystal structure data were given for the free base and the monohydrochloride forms.

IT 253797-00-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and x-ray crystallog. structure of 2-(4-amidinophenylaminomethyl))-1-methyl-5-(1-(carboxymethylamino)benzimidazole esters and/or salts for use as antithrombotic agents)

RN 253797-00-1 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:2693 HCAPLUS
DOCUMENT NUMBER: 140:53413
TITLE: Benzimidazole derivatives for the treatment of systemic inflammatory response syndrome
INVENTOR(S): Ries, Uwe; Wienen, Wolfgang; Schuly, Uwe
PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004000310	A1	20031231	WO 2003-EP6318		20030616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
DE 10227668	A1	20040108	DE 2002-10227668		20020620
CA 2489545	A1	20031231	CA 2003-2489545		20030616
AU 2003278945	A1	20040106	AU 2003-278945		20030616
EP 1517687	A1	20050330	EP 2003-740255		20030616
EP 1517687	B1	20070620			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006514603	T	20060511	JP 2004-514727		20030616
AT 365038	T	20070715	AT 2003-740255		20030616
ES 2289305	T3	20080201	ES 2003-740255		20030616
US 2004023975	A1	20040205	US 2003-600055		20030620
PRIORITY APPLN. INFO.:			DE 2002-10227668	A	20020620
			US 2002-400166P	P	20020801
			WO 2003-EP6318	W	20030616

OTHER SOURCE(S): MARPAT 140:53413

AB The invention discloses the use of benzimidazole derivs. for producing a medicament used for treating the systemic inflammatory response syndrome and particularly sepsis. Preparation of (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)ethyl]benzimidazole hydrochloride is described.

IT 253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzimidazole derivs. for treatment of systemic inflammatory response syndrome)

RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:467997 HCAPLUS
DOCUMENT NUMBER: 135:61338
TITLE: Preparation of 2-(4-amidinophenylaminomethyl)benzimidazoles as antithrombotics
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962329	A1	20010628	DE 1999-19962329	19991223
US 2001006977	A1	20010705	US 2000-735159	20001212
US 6451832	B2	20020917		
CA 2393916	A1	20010705	CA 2000-2393916	20001216
WO 2001047896	A1	20010705	WO 2000-EP12841	20001216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244636	A1	20021002	EP 2000-983342	20001216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519129	T	20030617	JP 2001-549368	20001216
MX 2002PA06299	A	20021209	MX 2002-PA6299	20020621
US 2003004356	A1	20030102	US 2002-188952	20020703
US 6593355	B2	20030715		

PRIORITY APPLN. INFO.:

DE 1999-19962329	A	19991223
US 2000-175163P	P	20000107
US 2000-735159	A1	20001212
WO 2000-EP12841	W	20001216

OTHER SOURCE(S): MARPAT 135:61338

GI



AB Title compds. [I; R1 = alkyl, fluoroalkyl, pyrrolidinocarbonylalkyl, 2,5-dihydropyrrolocarbonylalkyl, aminoalkyl, etc., R2 = alkyl; R3 = carbamidoyl, cyano, (substituted) oxadiazolyl, etc.] and stereoisomerics thereof were prepared .Thus, (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(ethoxycarbonylmethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl] benzimidazole dihydrochloride in H2O was stirred with NaOH for 45 min. at room temperature followed by addition of HCl up to pH = 3.5 to give 100% (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl]benzimidazole dihydrochloride. Several I extended (doubled) the activated partial thromboplastin time (aPTT) with ED200 = 0.12-0.22 μM.

IT 253797-00-1P 345957-57-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylbenzimidazoles as antithrombotics)

RN 253797-00-1 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345957-57-5 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:34881 HCAPLUS
DOCUMENT NUMBER: 132:78556
TITLE: Preparation of amidinophenylaminomethylenzimidazoles as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001704	A2	20000113	WO 1999-EP4531	19990701
WO 2000001704	A3	20000406		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19829964	A1	20000105	DE 1998-19829964	19980704
DE 19857202	A1	20000615	DE 1998-19857202	19981211
DE 19912690	A1	20000921	DE 1999-19912690	19990320
CA 2337804	A1	20000113	CA 1999-2337804	19990701
AU 9949033	A	20000124	AU 1999-49033	19990701
AU 763094	B2	20030710		
BR 9911826	A	20010327	BR 1999-11826	19990701
EP 1095025	A2	20010502	EP 1999-932765	19990701
EP 1095025	B1	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100009	A	20020617	EE 2001-9	19990701
EE 4236	B1	20040216		

JP 2002519429	T	20020702	JP 2000-558106		19990701
AT 229511	T	20021215	AT 1999-932765		19990701
NZ 509625	A	20030829	NZ 1999-509625		19990701
SK 283744	B6	20031202	SK 2001-8		19990701
MX 2000PA12819	A	20040603	MX 2000-PA12819		20001219
IN 2000MN00760	A	20070615	IN 2000-MN760		20001221
NO 2001000028	A	20010103	NO 2001-28		20010103
BG 105111	A	20011231	BG 2001-105111		20010103
HR 2001000007	A1	20011231	HR 2001-7		20010103
HR 2001000007	B1	20030430			
HK 1036976	A1	20041119	HK 2001-107199		20011015
PRIORITY APPLN. INFO.:			DE 1998-19829964	A	19980704
			DE 1998-19857202	A	19981211
			DE 1999-19912690	A	19990320
			WO 1999-EP4531	W	19990701

OTHER SOURCE(S): MARPAT 132:78556

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, pyrazinylene, pyrimidinylene, pyridazinylene; A = alkylene; B = O, S, CH2, CO, imino, SO, SO2; R2 = R1COX, etc.; R1 = alkoxy, amino, alkylamino, dialkylamino, etc.; X = cycloalkylene; R3 = H, alkyl; R4 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride (multistep preparation given) showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P 253796-87-1P
253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253431-62-8 HCAPLUS
CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS
CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253796-87-1 HCAPLUS
CN Pyrrolidine, 1-[2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:15648 HCAPLUS
DOCUMENT NUMBER: 132:64257
TITLE: Preparation of amidinophenylaminomethylbenzimidazoles and related compounds as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 38 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19829964	A1	20000105	DE 1998-19829964	19980704
US 6248770	B1	20010619	US 1999-338970	19990624
TW 248435	B	20060201	TW 1999-88110926	19990629
CA 2337804	A1	20000113	CA 1999-2337804	19990701
WO 2000001704	A2	20000113	WO 1999-EP4531	19990701
WO 2000001704	A3	20000406		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

	ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU	9949033	A	20000124	AU	1999-49033	19990701
AU	763094	B2	20030710			
BR	9911826	A	20010327	BR	1999-11826	19990701
EP	1095025	A2	20010502	EP	1999-932765	19990701
EP	1095025	B1	20021211			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR	200100148	T2	20010921	TR	2001-148	19990701
EE	200100009	A	20020617	EE	2001-9	19990701
EE	4236	B1	20040216			
HU	2002000710	A2	20020629	HU	2002-710	19990701
HU	2002000710	A3	20030528			
JP	2002519429	T	20020702	JP	2000-558106	19990701
AT	229511	T	20021215	AT	1999-932765	19990701
PT	1095025	T	20030430	PT	1999-932765	19990701
ES	2188192	T3	20030616	ES	1999-932765	19990701
NZ	509625	A	20030829	NZ	1999-509625	19990701
SK	283744	B6	20031202	SK	2001-8	19990701
ZA	2000007624	A	20010716	ZA	2000-7624	20001219
MX	2000PA12819	A	20040603	MX	2000-PA12819	20001219
IN	2000MN00760	A	20070615	IN	2000-MN760	20001221
NO	2001000028	A	20010103	NO	2001-28	20010103
BG	105111	A	20011231	BG	2001-105111	20010103
HR	2001000007	A1	20011231	HR	2001-7	20010103
HR	2001000007	B1	20030430			
HK	1036976	A1	20041119	HK	2001-107199	20011015
PRIORITY APPLN. INFO.:				DE	1998-19829964 A	19980704
				US	1998-92215P P	19980709
				DE	1998-19857202 A	19981211
				DE	1999-19912690 A	19990320
				WO	1999-EP4531 W	19990701

OTHER SOURCE(S): MARPAT 132:64257

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, etc.; A = alkylene; B = O, S, CH2, CO, imino, sulfinyl, sulfonyl, etc.; R5 = R1COX; X = cycloalkylene; R1 = (substituted) (di)alkylamino, cycloalkyleneimino, morpholino, piperazino; R5 = H, alkyl; R7 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride [prepared starting from 1-(4-chlorophenyl)-1-cyclopropanecarboxylic acid] showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253431-62-8 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS

CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



=> d l13 ibib abs hitstr tot

L13 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2864 HCAPLUS
DOCUMENT NUMBER: 140:59935
TITLE: Preparation of crystalline (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazole esters and/or salts for use as antithrombotic agents
INVENTOR(S): Linz, Guenter; Sieger, Peter; Schreiner, Gunnar; Rall, Werner; Schmid, Rolf
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Gmbh & Co. Kg, Germany
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000818	A1	20031231	WO 2003-EP6317	20030616 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10227666	A1	20040108	DE 2002-10227666	20020620
CA 2485545	A1	20031231	CA 2003-2485545	20030616 <--
AU 2003237945	A1	20040106	AU 2003-237945	20030616
EP 1529035	A1	20050511	EP 2003-735629	20030616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508037	T	20060309	JP 2004-514726	20030616
US 2004010026	A1	20040115	US 2003-463033	20030617
US 7169934	B2	20070130		
US 2007099974	A1	20070503	US 2006-610187	20061213
US 7294721	B2	20071113		

PRIORITY APPLN. INFO.:		
DE 2002-10227666	A	20020620
US 2002-395188P	P	20020711
WO 2003-EP6317	W	20030616
US 2003-463033	A3	20030617

OTHER SOURCE(S): MARPAT 140:59935

AB The invention relates to the crystalline forms of compds. (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)-ethyl)-benzimidazole and monohydrochloride thereof, to methods for the production thereof, and to their use as medicaments having an antithrombotic action (no data). Thus, (R)-2-(4-cyanophenylaminomethyl)-1-methyl-5-[1-amino-1-(pyrrolidineocarbonyl)-ethyl]benzimidazole was simultaneously N-alkylated and CN-reduced/aminated

using BrCH2C(O)OCH2CH2CH3 in N-methylpyyolidinone, Pr acetate, and diisopropyethylamine; the resulting ester product was first isolated as the hydrochloride, and then as the 4-toluenesulfonic acid salt, which was deesterified to give the free base. The Et ester was similarly prepared Crystal structure data were given for the free base and the monohydrochloride forms.

IT 253797-00-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and x-ray crystallog. structure of 2-(4-amidinophenylaminomethyl))-1-methyl-5-(1-(carboxymethylamino)benzimidazole esters and/or salts for use as antithrombotic agents)

RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:2693 HCAPLUS
DOCUMENT NUMBER: 140:53413
TITLE: Benzimidazole derivatives for the treatment of systemic inflammatory response syndrome
INVENTOR(S): Ries, Uwe; Wienen, Wolfgang; Schuly, Uwe
PATENT ASSIGNEE(S): Boehringer Ingelheim, Germany
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000310	A1	20031231	WO 2003-EP6318	20030616 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10227668	A1	20040108	DE 2002-10227668	20020620
CA 2489545	A1	20031231	CA 2003-2489545	20030616 <--
AU 2003278945	A1	20040106	AU 2003-278945	20030616
EP 1517687	A1	20050330	EP 2003-740255	20030616
EP 1517687	B1	20070620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514603	T	20060511	JP 2004-514727	20030616
AT 365038	T	20070715	AT 2003-740255	20030616
ES 2289305	T3	20080201	ES 2003-740255	20030616
US 2004023975	A1	20040205	US 2003-600055	20030620
PRIORITY APPLN. INFO.:			DE 2002-10227668 A	20020620
			US 2002-400166P P	20020801
			WO 2003-EP6318 W	20030616

OTHER SOURCE(S): MARPAT 140:53413

AB The invention discloses the use of benzimidazole derivs. for producing a medicament used for treating the systemic inflammatory response syndrome and particularly sepsis. Preparation of (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-(pyrrolidinocarbonyl)ethyl]benzimidazole hydrochloride is described.

IT 253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(benzimidazole derivs. for treatment of systemic inflammatory response syndrome)

RN 253797-00-1 HCAPLUS

CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:467997 HCAPLUS

DOCUMENT NUMBER: 135:61338

TITLE: Preparation of 2-(4-amidinophenylaminomethyl)benzimidazoles as antithrombotics

INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang

PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany

SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19962329	A1	20010628	DE 1999-19962329	19991223 <--
US 2001006977	A1	20010705	US 2000-735159	20001212 <--
US 6451832	B2	20020917		
CA 2393916	A1	20010705	CA 2000-2393916	20001216 <--
WO 2001047896	A1	20010705	WO 2000-EP12841	20001216 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244636	A1	20021002	EP 2000-983342	20001216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519129	T	20030617	JP 2001-549368	20001216 <--
MX 2002PA06299	A	20021209	MX 2002-PA6299	20020621 <--
US 2003004356	A1	20030102	US 2002-188952	20020703 <--
US 6593355	B2	20030715		

PRIORITY APPLN. INFO.:	DE 1999-19962329	A	19991223
	US 2000-175163P	P	20000107
	US 2000-735159	A1	20001212
	WO 2000-EP12841	W	20001216

OTHER SOURCE(S): MARPAT 135:61338
GI



I

AB Title compds. [I; R1 = alkyl, fluoroalkyl, pyrrolidinocarbonylalkyl, 2,5-dihydropyrrolocarbonylalkyl, aminoalkyl, etc., R2 = alkyl; R3 = carbamidoyl, cyano, (substituted) oxadiazolyl, etc.] and stereoisomerics thereof were prepared .Thus, (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(ethoxycarbonylmethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl] benzimidazole dihydrochloride in H2O was stirred with NaOH for 45 min. at room temperature followed by addition of HCl up to pH = 3.5 to give 100% (R)-2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(carboxymethylamino)-1-[(R,S)-2-methylpyrrolidinocarbonyl]ethyl]benzimidazole dihydrochloride. Several I extended (doubled) the activated partial thromboplastin time (aPTT) with ED200 = 0.12-0.22 μM.

IT 253797-00-1P 345957-57-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylbenzimidazoles as antithrombotics)

RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345957-57-5 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:34881 HCAPLUS
DOCUMENT NUMBER: 132:78556
TITLE: Preparation of amidinophenylaminomethylenzimidazoles as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001704	A2	20000113	WO 1999-EP4531	19990701 <--

WO 2000001704	A3	20000406			
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
DE 19829964	A1	20000105	DE 1998-19829964		19980704 <--
DE 19857202	A1	20000615	DE 1998-19857202		19981211 <--
DE 19912690	A1	20000921	DE 1999-19912690		19990320 <--
CA 2337804	A1	20000113	CA 1999-2337804		19990701 <--
AU 9949033	A	20000124	AU 1999-49033		19990701 <--
AU 763094	B2	20030710			
BR 9911826	A	20010327	BR 1999-11826		19990701 <--
EP 1095025	A2	20010502	EP 1999-932765		19990701 <--
EP 1095025	B1	20021211			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
EE 200100009	A	20020617	EE 2001-9		19990701 <--
EE 4236	B1	20040216			
JP 2002519429	T	20020702	JP 2000-558106		19990701 <--
AT 229511	T	20021215	AT 1999-932765		19990701 <--
NZ 509625	A	20030829	NZ 1999-509625		19990701 <--
SK 283744	B6	20031202	SK 2001-8		19990701 <--
MX 2000PA12819	A	20040603	MX 2000-PA12819		20001219
IN 2000MN00760	A	20070615	IN 2000-MN760		20001221
NO 2001000028	A	20010103	NO 2001-28		20010103 <--
BG 105111	A	20011231	BG 2001-105111		20010103 <--
HR 2001000007	A1	20011231	HR 2001-7		20010103 <--
HR 2001000007	B1	20030430			
HK 1036976	A1	20041119	HK 2001-107199		20011015
PRIORITY APPLN. INFO.:			DE 1998-19829964	A	19980704
			DE 1998-19857202	A	19981211
			DE 1999-19912690	A	19990320
			WO 1999-EP4531	W	19990701

OTHER SOURCE(S): MARPAT 132:78556

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, pyrazinylene, pyrimidinylene, pyridazinylene; A = alkylene; B = O, S, CH2, CO, imino, SO, SO2; R2 = R1COX, etc.; R1 = alkoxy, amino, alkylamino, dialkylamino, etc.; X = cycloalkylene; R3 = H, alkyl; R4 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride (multistep preparation given) showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P 253796-87-1P
253797-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylenzimidazoles as antithrombotics)

RN 253431-62-8 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS

CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253796-87-1 HCAPLUS
CN Pyrrolidine, 1-[2-amino-2-[1-methyl-2-[[[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]amino]methyl]-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 253797-00-1 HCAPLUS
CN Pyrrolidine, 1-[(2R)-2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L13 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:15648 HCAPLUS
DOCUMENT NUMBER: 132:64257
TITLE: Preparation of amidinophenylaminomethylbenzimidazoles and related compounds as antithrombotics.
INVENTOR(S): Ries, Uwe; Kauffmann, Iris; Hauel, Norbert; Priepke, Henning; Nar, Herbert; Stassen, Jean Marie; Wienen, Wolfgang
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: Ger. Offen., 38 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19829964	A1	20000105	DE 1998-19829964	19980704 <--
US 6248770	B1	20010619	US 1999-338970	19990624 <--
TW 248435	B	20060201	TW 1999-88110926	19990629
CA 2337804	A1	20000113	CA 1999-2337804	19990701 <--
WO 2000001704	A2	20000113	WO 1999-EP4531	19990701 <--
WO 2000001704	A3	20000406		

W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9949033		A	20000124	AU 1999-49033	19990701 <--
AU 763094		B2	20030710		
BR 9911826		A	20010327	BR 1999-11826	19990701 <--
EP 1095025		A2	20010502	EP 1999-932765	19990701 <--
EP 1095025		B1	20021211		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100148		T2	20010921	TR 2001-148	19990701 <--
EE 200100009		A	20020617	EE 2001-9	19990701 <--
EE 4236		B1	20040216		
HU 2002000710		A2	20020629	HU 2002-710	19990701 <--
HU 2002000710		A3	20030528		
JP 2002519429		T	20020702	JP 2000-558106	19990701 <--
AT 229511		T	20021215	AT 1999-932765	19990701 <--
PT 1095025		T	20030430	PT 1999-932765	19990701 <--
ES 2188192		T3	20030616	ES 1999-932765	19990701 <--
NZ 509625		A	20030829	NZ 1999-509625	19990701 <--
SK 283744		B6	20031202	SK 2001-8	19990701 <--
ZA 2000007624		A	20010716	ZA 2000-7624	20001219 <--
MX 2000PA12819		A	20040603	MX 2000-PA12819	20001219
IN 2000MN00760		A	20070615	IN 2000-MN760	20001221
NO 2001000028		A	20010103	NO 2001-28	20010103 <--
BG 105111		A	20011231	BG 2001-105111	20010103 <--
HR 2001000007		A1	20011231	HR 2001-7	20010103 <--
HR 2001000007		B1	20030430		
HK 1036976		A1	20041119	HK 2001-107199	20011015
PRIORITY APPLN. INFO.:				DE 1998-19829964	A 19980704
				US 1998-92215P	P 19980709
				DE 1998-19857202	A 19981211
				DE 1999-19912690	A 19990320
				WO 1999-EP4531	W 19990701

OTHER SOURCE(S): MARPAT 132:64257

GI



I

AB Title compds. [I; Ar = (substituted) phenylene, naphthylene, thienylene, thiazolylene, pyridinylene, etc.; A = alkylene; B = O, S, CH2, CO, imino, sulfinyl, sulfonyl, etc.; R5 = R1COX; X = cycloalkylene; R1 = (substituted) (di)alkylamino, cycloalkyleneimino, morpholino, piperazino; R5 = H, alkyl; R7 = cyano, (substituted) amidino], were prepared Thus, 2-(4-amidinophenylaminomethyl)-1-methyl-5-[1-(pyrrolidin-1-ylcarbonyl)cyclopropyl]benzimidazole hydrochloride [prepared starting from

1-(4-chlorophenyl)-1-cyclopropanecarboxylic acid] showed aPTT (partial thrombin time) ED200 = 0.12 μM.

IT 253430-83-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253430-83-0 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[[4-(aminoiminomethyl)phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 253431-62-8P 253431-65-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amidinophenylaminomethylbenzimidazoles and related compds. as antithrombotics)

RN 253431-62-8 HCAPLUS

CN Pyrrolidine, 1-[amino[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]acetyl]- (9CI) (CA INDEX NAME)



RN 253431-65-1 HCAPLUS

CN Pyrrolidine, 1-[2-amino-2-[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)



=> d l14 ibib abs hitstr tot

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1156435 HCAPLUS
DOCUMENT NUMBER: 142:86665
TITLE: Cyclohexylglycine derivatives as dipeptidyl peptidase IV inhibitors for the treatment or prevention of diabetes and other dipeptidyl peptidase IV-associated diseases
INVENTOR(S): Edmondson, Scott D.; Mastracchio, Anthony; Parmee, Emma R.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004112701	A2	20041229	WO 2004-US18718		20040610
WO 2004112701	A3	20050210			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004249163	A1	20041229	AU 2004-249163		20040610
CA 2527806	A1	20041229	CA 2004-2527806		20040610
EP 1638950	A2	20060329	EP 2004-755091		20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1809544	A	20060726	CN 2004-80016974		20040610
JP 2006528131	T	20061214	JP 2006-517234		20040610
IN 2005DN05637	A	20080201	IN 2005-DN5637		20051205
US 2007021477	A1	20070125	US 2005-560771		20051213
PRIORITY APPLN. INFO.:			US 2003-479246P	P	20030617
			WO 2004-US18718	W	20040610

OTHER SOURCE(S): MARPAT 142:86665

AB The invention discloses cyclohexylglycine derivs. which are inhibitors of dipeptidyl peptidase IV which are useful in the treatment or prevention of diseases in which dipeptidyl peptidase IV is involved, such as diabetes and particularly type 2 diabetes. The invention also discloses pharmaceutical compns. comprising these compds. and the use of these compds. and compns. in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved. Preparation of compds. and intermediates is described.

IT 815580-74-6 815580-74-6D, derivs. 815580-75-7 815580-75-7D, derivs. 815580-76-8 815580-76-8D, derivs. 815580-77-9 815580-77-9D, derivs. 815580-79-1 815580-79-1D, derivs. 815580-80-4 815580-80-4D, derivs. 815580-87-1 815580-87-1D, derivs. 815580-88-2 815580-88-2D, derivs. 815580-89-3 815580-89-3D, derivs. 815580-90-6 815580-90-6D, derivs. 815580-91-7 815580-91-7D, derivs. 815580-92-8 815580-92-8D, derivs. 815580-93-9 815580-93-9D, derivs. 815580-94-0 815580-94-0D, derivs. 815580-95-1 815580-95-1D, derivs. 815580-96-2 815580-96-2D, derivs. 815580-97-3 815580-97-3D, derivs. 815580-98-4 815580-98-4D, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclohexylglycine derivs. as dipeptidyl peptidase IV inhibitors for treatment or prevention of diabetes and other dipeptidyl peptidase IV-associated diseases)

RN 815580-74-6 HCAPLUS

CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-74-6 HCAPLUS

CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-75-7 HCAPLUS

CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-75-7 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-76-8 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-76-8 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-77-9 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-77-9 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-79-1 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-79-1 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-80-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-

difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-80-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzothiazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-87-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-87-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-88-2 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-88-2 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-89-3 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-89-3 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-90-6 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-90-6 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-91-7 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-91-7 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3-
fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-92-8 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-
difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-92-8 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-5-benzoxazolyl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-93-9 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-93-9 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 815580-94-0 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-94-0 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 815580-95-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-95-1 HCAPLUS
CN Pyrrolidine, 1-[amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 815580-96-2 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-96-2 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-97-3 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-97-3 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-98-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-

3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 815580-98-4 HCAPLUS
CN Pyrrolidine, 1-[(2S)-amino(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)acetyl]-
3,3-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	81.54	671.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.60	-13.60

STN INTERNATIONAL LOGOFF AT 11:15:04 ON 14 FEB 2008